EGFR and colorectal carcinoma: Collectively, these data indicated that anlotinib could suppress tumor metastasis, angiogenesis, and multidrug resistance which reduced MET, EGFR, and ABCB1 expression in CRC liver metastasis and subcutaneously implanted xenograft model (Fig. 5I).